glp 1 drugs heart failure Benefits of GLP-1s Disappear Fast if You Stop Taking The GLP-1 drugs may prevent no-reflow

Performance analysis of the proposed model and various ML algorithms The comparative analysis presented in Table 5 clearly shows that the projected CNN-LSTM patch-wise model outperforms several existing models on various datasets

The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough

Health care expenditures, age, proximity to death and morbidity: implications for an ageing population

Circulating Th17 cytokine levels are altered in Hashimotos thyroiditis

JACS Au